Skip to content
6-K

Foreign Interim / Material

Calliditas Therapeutics AB

0001410578-24-001370

← back to feed
Filed
Aug 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q2 2024 · Jun 30, 2024 −7.04M
Operating Cash Flow Q2 2024 · Jun 30, 2024 −205.25M
Operating Cash Flow Q2 2024 · Dec 31, 2023 −434.66M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −163.03M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −394.97M
Cash And Equivalents Q2 2024 · Jun 30, 2024 797.28M
Cash And Equivalents Q2 2024 · Mar 31, 2024 810.32M
Cash And Equivalents Q2 2024 · Dec 31, 2023 973.73M
Cash And Equivalents Q2 2024 · Jun 30, 2023 866.18M
Cash And Equivalents Q2 2024 · Mar 31, 2023 1.01B
Cash And Equivalents Q2 2024 · Dec 31, 2022 1.25B
Stockholders Equity Q2 2024 · Jun 30, 2024 106.79M
Stockholders Equity Q2 2024 · Dec 31, 2023 334.81M
Stockholders Equity Q2 2024 · Jun 30, 2023 504.37M
Current Liabilities Q2 2024 · Jun 30, 2024 429.78M
Current Liabilities Q2 2024 · Dec 31, 2023 407.14M
Current Liabilities Q2 2024 · Jun 30, 2023 290.31M
Current Assets Q2 2024 · Jun 30, 2024 1.15B
Current Assets Q2 2024 · Dec 31, 2023 1.28B
Current Assets Q2 2024 · Jun 30, 2023 1.11B
Total Assets Q2 2024 · Jun 30, 2024 1.75B
Total Assets Q2 2024 · Dec 31, 2023 1.86B
Total Assets Q2 2024 · Jun 30, 2023 1.71B
Eps Diluted Q2 2024 · Jun 30, 2024 −0.88
Eps Diluted Q2 2024 · Jun 30, 2024 −5.47
Eps Diluted Q2 2024 · Dec 31, 2023 −8.69
Eps Diluted Q2 2024 · Jun 30, 2023 −1.71
Eps Diluted Q2 2024 · Jun 30, 2023 −5.21
Eps Basic Q2 2024 · Jun 30, 2024 −0.88
Eps Basic Q2 2024 · Jun 30, 2024 −5.47
Eps Basic Q2 2024 · Dec 31, 2023 −8.69
Eps Basic Q2 2024 · Jun 30, 2023 −1.71
Eps Basic Q2 2024 · Jun 30, 2023 −5.21
Rd Expense Q2 2024 · Jun 30, 2024 120.72M
Rd Expense Q2 2024 · Jun 30, 2024 271.33M
Rd Expense Q2 2024 · Dec 31, 2023 502.22M
Rd Expense Q2 2024 · Jun 30, 2023 88.99M
Rd Expense Q2 2024 · Jun 30, 2023 215.64M
Net Income Q2 2024 · Jun 30, 2024 −47.48M
Net Income Q2 2024 · Jun 30, 2024 −293.64M
Net Income Q2 2024 · Dec 31, 2023 −466.19M
Net Income Q2 2024 · Jun 30, 2023 −91.93M
Net Income Q2 2024 · Jun 30, 2023 −279.46M
Operating Income Q2 2024 · Jun 30, 2024 −31.5M
Operating Income Q2 2024 · Jun 30, 2024 −235.33M
Operating Income Q2 2024 · Dec 31, 2023 −373.06M
Operating Income Q2 2024 · Jun 30, 2023 −75.17M
Operating Income Q2 2024 · Jun 30, 2023 −255.25M
Gross Profit Q2 2024 · Jun 30, 2024 506.33M
Gross Profit Q2 2024 · Jun 30, 2024 787.8M
Gross Profit Q2 2024 · Dec 31, 2023 1.15B
Gross Profit Q2 2024 · Jun 30, 2023 255.17M
Gross Profit Q2 2024 · Jun 30, 2023 437.49M
Cost Of Revenue Q2 2024 · Jun 30, 2024 53.45M
Cost Of Revenue Q2 2024 · Jun 30, 2024 67.46M
Cost Of Revenue Q2 2024 · Dec 31, 2023 60.46M
Cost Of Revenue Q2 2024 · Jun 30, 2023 14.21M
Cost Of Revenue Q2 2024 · Jun 30, 2023 23.24M